Collplant Biotechnologies Ltd. · NASDAQ:CLGN
Collplant Biotechnologies — Investor Presentation (April 2022)
23 slides from Collplant Biotechnologies's investor presentation, Apr 14, 2022
Slide 1: CollPlant Overview April 2022
CollPlant Overview April 2022
Slide 2: Safe harbor statement
Safe harbor statement Certain statements in this presentation constitute "forward - looking statements" within the meaning of Section 27 A of the Securities Act and Section 21 E of the Securities Exchange Act and are usually identified by the use of words such as "anticipates," "believes," "estimate
Slide 3: CollPlant – Unlocking the Regenerative Potential of rhCollagen
3 CollPlant – Unlocking the Regenerative Potential of rhCollagen Collaboration Agreements with Industry Leaders • AbbVie (ABBV) - Worldwide exclusive agreement for dermal and soft tissue fillers. Up to $103mm in payments plus royalties. • 3D Systems (DDD) - Bioprinted solutions for breast reconstruc
Slide 4: Expressing human genes: plant-based platform produces human collagen at mass scale
4 Expressing 5 human genes Plant - based platform produces human collagen in mass - scale
Slide 5: rhCollagen - The ideal building block for regenerative medicine implants
rhCollagen - The ideal building block for regenerative medicine implants 5 Animal Extracted Plant - derived Clear advantages over tissue - extracted collagen Better bio - functionality Superior homogeneity Improved safety and greater purity Cell binding domains
Slide 6: Product Pipeline
Product Pipeline Aesthetic medicine Regenerative medicine Dermal/soft tissue fillers BioInk formulations Photocurable dermal filler Injectable breast implants Soft and hard tissues Collaboration with 3D bioprinted products Breast implants Regenerative Tissue Matrix for breast reconstruction
Slide 7: Dermal/Soft Tissue Fillers
Dermal/Soft Tissue Fillers In collaboration with
Slide 8: Dermal fillers market overview
Dermal fillers market overview ~2.6 M HA procedures in 2020 in the US 1 $5B, 9.6% CAGR Global dermal filler market, 2021, CAGR 2022 - 2028 2 $100 - $250/unit Cost per syringe 3 8 1. 2. 3. https://www.plasticsurgery.org/documents/News/Statistics/2020/plastic - surgery - statistics - full - report - 2
Slide 9: Collaboration agreement with AbbVie
9 Collaboration agreement with AbbVie Agreement highlights: A worldwide exclusive development and commercialization agreement for dermal and soft tissue fillers for the medical aesthetics market Financial highlights: Up to $103M in potential payments, including: • $14M upfront payment • Up to $89M m
Slide 10: rhCollagen-based photocurable regenerative dermal filler
rhCollagen - based photocurable regenerative dermal filler * key attributes Photocuring in - situ Tissue regeneration Good tissue retention Sculpting before curing Easy injection (30G needle) Optimized post curing stiffness Injection Sculpting *AbbVie’s Option Product http://collplant.com/products/p
Slide 11: 3D Bioprinted Tissues and Organs
3D Bioprinted Tissues and Organs
Slide 12: 3D bioprinting represents a wide range of development opportunities
12 In - house Development Collaboration with tier - 1 Development cost Time to market Tissues ● Breast ● Heart valve ● Cornea ● Skin ● Cartilage Endocrine glands ● Ovary ● Pancreas ● Thyroid Organs ● Lungs ● Kidney ● Liver ● Heart Scaffolds ● Spine fusion ● Tendons, ligaments ● Bones ● Nerve conduit
Slide 13: Breast Reconstruction / Augmentation
Breast Reconstruction / Augmentation
Slide 14: Breast implants market overview
Breast implants market overview Current breast reconstruction is based on synthetic breast implantation, free flap surgery/autologous fat tissue transfer - all of which replace tissue rather than regenerate it. $2.8B Market worldwide (2019) 1 $ 5 - 10K Cost per full procedure in US 2 ~2,200,000 Brea
Slide 15: CollPlant's 3D bioprinted breast implants
15 CollPlant’s 3D bioprinted breast implants * Breast scaffold bioprinting rhCollagen + ECM** components Implantation and vascularization Implant replacement by newly formed tissue * Study on large animals will be initiated in Q2 2022 ** ECM - extracellular matrix
Slide 16: rhCollagen-based regenerative tissue matrix
Provide extra coverage, direct - to - implant reconstruction and superior cosmetic results US: mostly human - sourced (93%) EU: mostly animal - sourced Used in 61% of U.S. breast reconstruction surgeries Breast reconstruction procedures using ADMS /yr (US): 60K Market potential (US) $600Mn Surgical
Slide 17: Injectable breast implants
Injectable breast implants* 17 • Composed of rhCollagen and additional materials, intended to promote breast tissue regeneration • Designed to attract cells to promote tissue regeneration and support the viability and function of the newly regenerated tissue • The scaffold is designed to gradually d
Slide 18: rhCollagen BioInk compositions in development
rhCollagen BioInk compositions in development Direct Ink Writing (DIW) Inkjet Projection Stereolithography Laser Induced Forward Transfer (LIFT) Polymers (physical properties) Ceramics (hard tissue) Nanoparticles (sustained release/ physical properties ( ECM components (biological/ physical properti
Slide 19: Collink.3D human collagen bioink platform
CollPlant now offers Collink.3D TM , human collagen bioink platform, for 3D bioprinting of organs, scaffolds and tissue models for drug discovery, personalized medicine and regenerative medicine applications. 19
Slide 20: Our Partners
Our Partners Companies Consortiums & organizations Development and commercialization agreement Joint development agreement Universal BioInk Industry committee Scalable manufacturing of tissue engineered products 20 Collaboration agreement Supply agreement
Slide 21: Experienced management team
Yehiel Tal CEO Regentis Biomaterials ProChon Biotech Kulicke & Soffa Industries Eran Rotem Deputy CEO & CFO Tefron, CFO (NYSE,TASE) Healthcare Tech., CFO (NASDAQ) & Gamida E&Y Ilana Belzer, PhD COO BioHarvest Procognia Ltd. Omrix Biopharmaceuticals Interpharm Michal Roytman VP Sales & Marketing Ocon
Slide 22: CollPlant investment thesis
CollPlant investment thesis Only commercially viable technology currently available that can produce truly human collagen Multi - billion dollar markets: innovative rhCollagen products initially aimed at 3D bioprinting and medical aesthetics Broadly applicable technology: Ideal building block/scaffo
Slide 23: CollPlant - Thank you
CollPlant | een Thank you
CollPlant Biotechnologies — Investor Presentation (April 2022) on 6ix